| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Serine/threonine-protein kinase PLK1 |
|---|
| Ligand | BDBM50595396 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | ChEMBL_2216648 (CHEMBL5129780) |
|---|
| IC50 | 17900±n/a nM |
|---|
| Citation |  Zhang, J; Zhang, L; Wang, J; Ouyang, L; Wang, Y Polo-like Kinase 1 Inhibitors in Human Cancer Therapy: Development and Therapeutic Potential. J Med Chem65:10133-10160 (2022) [PubMed] Article |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Serine/threonine-protein kinase PLK1 |
|---|
| Name: | Serine/threonine-protein kinase PLK1 |
|---|
| Synonyms: | PLK | PLK-1 | PLK1 | PLK1_HUMAN | Polo-like kinase 1 (PlK1) | Polo-like kinase 1 (Plk-1) | STPK13 | Serine/threonine-protein kinase (PLK1) | Serine/threonine-protein kinase 13 | polo-like kinase |
|---|
| Type: | Serine/threonine-protein kinase |
|---|
| Mol. Mass.: | 68277.16 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | P53350 |
|---|
| Residue: | 603 |
|---|
| Sequence: | MSAAVTAGKLARAPADPGKAGVPGVAAPGAPAAAPPAKEIPEVLVDPRSRRRYVRGRFLG
KGGFAKCFEISDADTKEVFAGKIVPKSLLLKPHQREKMSMEISIHRSLAHQHVVGFHGFF
EDNDFVFVVLELCRRRSLLELHKRRKALTEPEARYYLRQIVLGCQYLHRNRVIHRDLKLG
NLFLNEDLEVKIGDFGLATKVEYDGERKKTLCGTPNYIAPEVLSKKGHSFEVDVWSIGCI
MYTLLVGKPPFETSCLKETYLRIKKNEYSIPKHINPVAASLIQKMLQTDPTARPTINELL
NDEFFTSGYIPARLPITCLTIPPRFSIAPSSLDPSNRKPLTVLNKGLENPLPERPREKEE
PVVRETGEVVDCHLSDMLQQLHSVNASKPSERGLVRQEEAEDPACIPIFWVSKWVDYSDK
YGLGYQLCDNSVGVLFNDSTRLILYNDGDSLQYIERDGTESYLTVSSHPNSLMKKITLLK
YFRNYMSEHLLKAGANITPREGDELARLPYLRTWFRTRSAIILHLSNGSVQINFFQDHTK
LILCPLMAAVTYIDEKRDFRTYRLSLLEEYGCCKELASRLRYARTMVDKLLSSRSASNRL
KAS
|
|
|
|---|
| BDBM50595396 |
|---|
| n/a |
|---|
| Name | BDBM50595396 |
|---|
| Synonyms: | CHEMBL5196864 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C29H25N3O |
|---|
| Mol. Mass. | 431.5283 |
|---|
| SMILES | [H][C@@]12CN(Cc3cccc(c3)C#N)C[C@@]([H])(C1)c1c(ccc(=O)n1C2)-c1ccc2ccccc2c1 |r| |
|---|
| Structure | 
|
|---|
Search and Browse
